LifeSci Capital Initiates Coverage of Genkyotex

Developing Novel NOX Inhibitors to Treat Fibrotic and Inflammatory Conditions;
Report Available Here: http://www.lifescicapital.com/equity-research/genkyotex/

NEW YORK, NY / ACCESSWIRE / June 5, 2017 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of Genkyotex (Euronext Paris: GKTX.PA), a clinical stage biotechnology company focused on the development of anti-NADPH oxidase (NOX) enzyme therapies. The Company is developing lead asset GKT831, an inhibitor of NOX 1 and 4, for the treatment of primary biliary cholangitis (PBC) and potentially other fibrotic conditions. Genkyotex expects to initiate a Phase II study with GKT831 for PBC in the second quarter of 2017, and interim results are anticipated in the first half of 2018. The Company is also developing GKT771, a selective NOX 1 inhibitor, and plans to evaluate this compound for patients with inflammatory pain or possibly other related indications. Genkyotex plans to launch a Phase I pharmacodynamics study with GKT771, which is set to begin in the second half of 2017.

NOX enzymes play diverse roles in many biological processes, including inflammation and fibrosis. Expression of NOX4 is thought to be necessary for apoptosis in hepatocytes and hepatic stellate cell (HSC) activation, which subsequently leads to production of collagen and fibrosis. NOX1 has been shown to contribute to the pathogenesis of inflammatory pain, angiogenesis and other inflammatory and oxidative-stress related conditions. GKT831 is an inhibitor of NOX1 and NOX4, and as such there may be clinical value in using this product in PBC and NASH, among other fibrotic diseases affecting the liver, lungs, and kidneys. This product was assessed in a Phase II study for the treatment of individuals with diabetic kidney disease, and patients treated with GKT831 showed statistically significant reductions in gamma-glutamyl transferase (GGT) and high-sensitivity C-reactive protein (hsCRP) as compared to placebo (p < 0.05). Both markers are relevant to inflammatory and fibrotic liver indications, which has led the Company to assess this compound in PBC.

In a 30 page Initiation Report, LifeSci Capital describes the Company’s NOX inhibitors, how the products are differentiated from other therapies, and the market opportunities in the targeted indications.

Mr. Dolezal’s full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on Genkyotex as developments occur.

About LifeSci Capital:

LifeSci Capital LLC (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients’ businesses and the opportunities they are addressing. LifeSci Capital (www.lifescicapital.com) is a commonly-owned affiliate of LifeSci Advisors, LLC (www.lifesciadvisors.com). To learn more, please visit www.lifescipartners.com.

Analyst Contact:

Patrick Dolezal, M.S.
Phone: (212)915-2579
Email: pdolezal@lifescicapital.com

SOURCE: LifeSci Capital, LLC

ReleaseID: 464761